Please login to the form below

Not currently logged in
Email:
Password:

dermatitis

This page shows the latest dermatitis news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

Latest news

More from news
Approximately 7 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Phase II MAb to block IL-13 for treatment of atopic dermatitis.

  • Deal Watch September 2016 Deal Watch September 2016

    as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.

  • Deal Watch July 2016 Deal Watch July 2016

    AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis.

  • Allergies and asthma Allergies and asthma

    Early prevention is recommended. Allergic diseases (eg food allergies, rhinitis, asthma, atopic dermatitis) usually start in childhood but can develop at any age. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics